New pill shows promise for Hard-to-Treat cancers
NCT ID NCT07229898
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage study tests a new tablet called GEN-725 in 48 adults with advanced solid tumors that have stopped responding to standard treatments. The main goals are to check the drug's safety, how the body processes it, and whether it can shrink tumors. Participants must be between 18 and 75 years old and have no other standard options.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMORS are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Cancer Hospital of Shandong First Medical University (Shandong Cancer Institute, Shandong Cancer Hospital)
RECRUITINGJinan, China
-
Harbin Medical University Cancer Hospital
RECRUITINGHarbin, China
-
Shanghai East Hospital
RECRUITINGShanghai, China
-
The First Affiliated Hospital of Xinxiang Medical University
RECRUITINGXinxiang, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.